Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Other Non-Current Assets (2020 - 2026)

InMed Pharmaceuticals has reported Other Non-Current Assets over the past 5 years, most recently at $100000.0 for Q4 2025.

  • For Q4 2025, Other Non-Current Assets changed 0.0% year-over-year to $100000.0; the TTM value through Dec 2025 reached $100000.0, changed 0.0%, while the annual FY2025 figure was $100000.0, 0.0% changed from the prior year.
  • Other Non-Current Assets for Q4 2025 was $100000.0 at InMed Pharmaceuticals, roughly flat from $100000.0 in the prior quarter.
  • Over five years, Other Non-Current Assets peaked at $176637.0 in Q2 2022 and troughed at $8625.0 in Q3 2021.
  • A 5-year average of $106008.6 and a median of $100000.0 in 2023 define the central range for Other Non-Current Assets.
  • Biggest five-year swings in Other Non-Current Assets: soared 1884.12% in 2022 and later plummeted 41.56% in 2023.
  • Year by year, Other Non-Current Assets stood at $109175.0 in 2021, then skyrocketed by 56.75% to $171130.0 in 2022, then plummeted by 41.56% to $100000.0 in 2023, then changed by 0.0% to $100000.0 in 2024, then changed by 0.0% to $100000.0 in 2025.
  • Business Quant data shows Other Non-Current Assets for INM at $100000.0 in Q4 2025, $100000.0 in Q3 2025, and $100000.0 in Q2 2025.